Stock Fundamentals

Company Information

Company Name
Genmab AS
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US3723032062
CIK: 0001434265
CUSIP: 372303206
Currency: USD
Full Time Employees: 3,088
Phone: 45 70 20 27 28
Fiscal Year End: December
IPO Date: Jun 01, 2009
Description:

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Address:

Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500

Directors & Officers

Name Title Year Born
Dr. Jan G.J. van de Winkel Ph.D. Co-Founder, President & CEO 1961
Mr. Anthony Pagano CPA Executive VP & CFO 1978
Mr. Rayne Waller Executive VP & Chief Technical Operations Officer 1968
Mr. Gregory David Emil Mueller Executive VP, General Counsel & Chief Legal Officer 1971
Mr. Christopher Cozic Executive VP & Chief People Officer 1979
Dr. Martine J. van Vugt Ph.D. Executive VP & Chief Strategy Officer 1971
Mr. Martin Schultz Senior Director, Head of Development Business Partnership & Strategy and Director 1975
Dr. Judith V. Klimovsky M.D. Executive VP & Chief Development Officer 1958
Dr. Tahamtan Ahmadi M.D., Ph.D. Executive VP, Chief Medical Officer & Head of Experimental Medicines 1973
Dr. Mijke Zachariasse Ph.D. VP, Head of Antibody Research Materials & Director 1973

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Orbis Allan Gray Ltd 12.93M Mar 31, 2026 2.11% $1.46 -10.35%
AllianceBernstein L.P. 9.56M Mar 31, 2026 1.56% $0.10 -12.14%
Paradigm Biocapital Advisors LP 7.97M Mar 31, 2026 1.30% $4.37 13.18%
Arrowstreet Capital Limited Partnership 4.98M Mar 31, 2026 0.81% $0.07 -0.05%
BlackRock Inc 4.54M Mar 31, 2026 0.74% $0.00 -1.25%
Renaissance Technologies Corp 4.41M Mar 31, 2026 0.72% $0.19 26.39%
Deep Track Capital, LP 3.66M Mar 31, 2026 0.60% $1.61 0.00%
Harding Loevner L.P. 3.23M Mar 31, 2026 0.53% $0.89 -4.11%
Deerfield Management Co 2.46M Mar 31, 2026 0.40% $0.78 0.00%
First Trust Advisors L.P. 2.46M Mar 31, 2026 0.40% $0.05 84.33%
Two Sigma Investments LLC 2.34M Mar 31, 2026 0.38% $0.05 161.14%
Morgan Stanley - Brokerage Accounts 2.18M Mar 31, 2026 0.36% $0.00 19.09%
Federated Hermes Inc 1.25M Mar 31, 2026 0.20% $0.05 84.23%
Franklin Resources Inc 1.19M Mar 31, 2026 0.19% $0.01 3,792.81%
Pictet Asset Manangement SA 1.08M Mar 31, 2026 0.18% $0.03 -1.92%
Brandywine Global Investment Mgmt LLC 1.03M Dec 31, 2025 0.17% $0.21 -26.99%
FMR Inc 1.01M Mar 31, 2026 0.16% $0.00 -4.31%
Northern Trust Corp 950.53K Mar 31, 2026 0.15% $0.00 -0.68%
The Goldman Sachs Group Inc 931.26K Mar 31, 2026 0.15% $0.00 -30.15%
Millennium Management LLC 792.29K Mar 31, 2026 0.13% $0.01 737.76%

Shares Statistics

Shares Outstanding: 613.94M
Shares Float: 606.43M
% Insiders: 0.00%
% Institutions: 1,358.10%
Short % Float: 1.37%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 AllianceBernstein US L/C Growth Eqty MF 3.95M 0.64% ▲ 0.00% Apr 30, 2026
2 iShares Biotechnology ETF 3.52M 0.57% ▲ 1.46% May 29, 2026
3 Orbis SICAV Intl Eq Inv 3.09M 0.50% ▼ 9.01% Feb 28, 2026
4 First Trust NYSE Arca Biotech ETF 2.73M 0.45% ▼ 0.43% May 31, 2026
5 AB Large Cap Growth A 1.85M 0.30% ▲ 0.00% Apr 30, 2026
6 Orbis SICAV Global Bal Instl Inv 1.41M 0.23% ▲ 59.98% Sep 30, 2025
7 Orbis Global Equity Investor 1.31M 0.21% ▲ 0.00% Dec 31, 2025
8 AB US Large Cap Growth CT B 988.04K 0.16% ▼ 0.71% Apr 30, 2026
9 American Growth One D 949.87K 0.15% ▲ 0.00% Apr 30, 2026
10 AB American Growth AX USD 947.38K 0.15% ▼ 0.20% Apr 30, 2026

Valuation Metrics

Enterprise Value: $21.26B
Trailing P/E: 22.14
Forward P/E: 17.15

Financial Highlights

Market Cap: $17.80B
EBITDA: $1.33B
P/E Ratio: $22.14
PEG Ratio: $1.93
Book Value: $9.26
Earnings/Share: $1.31
Profit Margin: 21.05%
Operating Margin: 25.11%
ROA (TTM): 8.48%
ROE (TTM): 14.96%
Revenue (TTM): $3.90B
Revenue/Share (TTM): $6.29
Earnings Growth (YOY): -72.80%
Revenue Growth (YOY): 25.30%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 2.02x 0.91x 0.55x 20.49x 3.96x
2024-12-31 5.25x 0.00x 0.20x 55.86x 0.01x
2023-12-31 13.34x 0.00x 0.10x 197.07x 0.02x
2022-12-31 15.48x 0.00x 0.09x 298.43x 0.01x
2021-12-31 14.50x 0.00x 0.10x 227.15x 0.01x
2020-12-31 15.00x 0.00x 0.10x 631.30x 0.01x
2019-12-31 14.88x 0.00x 0.07x 376.86x 0.01x
2018-12-31 16.77x 0.00x 0.05x 3,310.03x 0.00x
2017-12-31 18.52x 0.00x 0.05x 672.09x 0.00x
2016-12-31 11.90x 0.01x 0.08x 4,942.88x 0.05x
2015-12-31 8.85x 0.00x 0.11x 6,189.65x 0.00x
2014-12-31 4.22x 0.00x 0.29x 65.41x 0.00x
2013-12-31 1.87x 0.00x 0.62x 20.82x 0.03x
2012-12-31 1.40x 0.01x 0.77x -42.87x -0.04x
2011-12-31 1.55x 0.02x 0.69x -122.63x -0.06x
2010-12-31 1.83x 0.11x 0.56x -4.05x -1.97x
2009-12-31 2.41x 0.01x 0.42x -2.75x -0.09x
2008-12-31 1.85x 0.00x 0.33x -3.30x -0.01x
2007-12-31 3.67x 0.00x 0.27x -402.31x -0.02x
2006-12-31 9.53x 0.00x 0.11x -467.96x -0.02x
2005-12-31 5.58x 0.01x 0.18x -316.28x -0.02x
2004-12-31 17.04x 0.01x 0.07x 6.43x 0.01x
2003-12-31 14.21x 0.01x 0.08x 4.09x 0.01x
2002-12-31 8.84x 0.00x 0.12x -4.81x 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GMAB.US!